Antidepressant medications are the most common treatment for major depression and
related disorders. Pharmacogenetic studies have demonstrated that response to these …

Major depressive disorder (MDD) is the leading cause of disability worldwide and is
associated with high rates of suicide and medical comorbidities. Current antidepressant …

Major Depressive Disorder (MDD) is a widespread debilitating neuropsychiatric disorder.
While a broad range of drugs to treat MDD are available, a large portion of the patients fail to …

Background Evidence has supported a role of DNA methylation in the pathophysiology of
mood disorders. The purpose of the current study is to examine 5-methylcytosine (5-mc) and …

Although the currently available antidepressants are well established in the treatment of the
major depressive disorder (MDD), there is strong variability in the response of individual …

There has been a limited number of systematic reviews conducted to summarize the
overview of the relationship between DNA methylation and depression, and to critically …

Aim: To identify the DNA methylation status of related genes in major depressive disorder
following selective serotonin-reuptake inhibitor treatment. Materials & methods: 45 patients …

Pharmacotherapy is the most common treatment for schizophrenia (SCZ), bipolar disorder
(BD), and major depressive disorder (MDD). Pharmacogenetic studies have achieved …

Background The serotonin transporter gene (SLC6A4; 5-HTT; SERT) is considered a prime
candidate in pharmacogenetic research in major depressive disorder (MDD). Besides …

Background: Antidepressants have variable therapeutic effects, depending on genetic and
environmental factors. Approximately 30% of major depressive disorder (MDD) patients do …